Sanofi India Ltd
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]
- Market Cap ₹ 7,375 Cr.
- Current Price ₹ 3,202
- High / Low ₹ 4,638 / 2,758
- Stock P/E 16.7
- Book Value ₹ 374
- Dividend Yield 2.34 %
- ROCE 49.2 %
- ROE 47.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company's working capital requirements have reduced from 27.6 days to 20.4 days
Cons
- Stock is trading at 8.56 times its book value
- Debtor days have increased from 32.9 to 41.7 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2014 (S) | Dec 2015 (S) | Dec 2016 (S) | Dec 2017 (S) | Dec 2018 (S) | Dec 2019 (S) | Dec 2020 (S) | Dec 2021 (S) | Dec 2022 (S) | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,977 | 2,193 | 2,367 | 2,460 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 1,996 | 2,013 | |
| Sales growth | +9% | +11% | +8% | +4% | +13% | +11% | -5% | +2% | -6% | +1% | |
| 1,639 | 1,817 | 1,832 | 1,921 | 2,146 | 2,403 | 2,186 | 2,194 | 2,066 | 1,508 | 1,522 | |
| Operating Profit | 339 | 376 | 535 | 538 | 625 | 667 | 716 | 762 | 704 | 488 | 491 |
| OPM % | 17% | 17% | 23% | 22% | 23% | 22% | 25% | 26% | 25% | 24% | 24% |
| 131 | 218 | 66 | 79 | 88 | 33 | 45 | 564 | 204 | 317 | 78 | |
| Interest | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 97 | 113 | 119 | 102 | 103 | 100 | 82 | 67 | 42 | 36 | 37 |
| Profit before tax | 373 | 481 | 480 | 515 | 610 | 600 | 677 | 1,258 | 864 | 767 | 531 |
| Tax % | 29% | 33% | 37% | 37% | 38% | 31% | 29% | 25% | 28% | 21% | 22% |
| 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 621 | 603 | 413 | |
| EPS in Rs | 114.61 | 139.78 | 132.26 | 141.74 | 165.48 | 180.09 | 207.65 | 410.61 | 269.83 | 262.13 | 179.70 |
| Dividend Payout % | 39% | 46% | 51% | 50% | 51% | 194% | 176% | 119% | 211% | 64% | 65% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -9% |
| 3 Years: | -12% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 47% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2014 (S) | Dec 2015 (S) | Dec 2016 (S) | Dec 2017 (S) | Dec 2018 (S) | Dec 2019 (S) | Dec 2020 (S) | Dec 2021 (S) | Dec 2022 (S) | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
| Reserves | 1,463 | 1,604 | 1,860 | 2,003 | 2,196 | 2,419 | 2,096 | 2,203 | 1,253 | 992 | 838 |
| 0 | 0 | 0 | 0 | 0 | 0 | 23 | 25 | 24 | 19 | 19 | |
| 742 | 778 | 658 | 751 | 765 | 802 | 777 | 811 | 772 | 681 | 732 | |
| Total Liabilities | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 |
| 648 | 877 | 817 | 769 | 733 | 499 | 464 | 334 | 306 | 315 | 312 | |
| CWIP | 210 | 22 | 34 | 30 | 21 | 17 | 10 | 13 | 24 | 16 | 18 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,369 | 1,505 | 1,690 | 1,978 | 2,230 | 2,728 | 2,444 | 2,714 | 1,743 | 1,384 | 1,281 | |
| Total Assets | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2014 (S) | Dec 2015 (S) | Dec 2016 (S) | Dec 2017 (S) | Dec 2018 (S) | Dec 2019 (S) | Dec 2020 (S) | Dec 2021 (S) | Dec 2022 (S) | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 265 | 213 | 322 | 435 | 374 | 412 | 611 | 559 | 399 | 230 | 462 | |
| 61 | 36 | -155 | -79 | -73 | 66 | 276 | 631 | 651 | 38 | -180 | |
| -122 | -147 | -180 | -188 | -197 | -183 | -810 | -849 | -1,583 | -878 | -392 | |
| Net Cash Flow | 205 | 102 | -13 | 168 | 104 | 295 | 78 | 341 | -533 | -610 | -111 |
| Free Cash Flow | 247 | 184 | 253 | 379 | 317 | 337 | 810 | 574 | 412 | 220 | 426 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 114% | 93% | 101% | 118% | 99% | 96% | 112% | 111% | 94% | 97% | 114% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
Consolidated / View Standalone
| Dec 2014 (S) | Dec 2015 (S) | Dec 2016 (S) | Dec 2017 (S) | Dec 2018 (S) | Dec 2019 (S) | Dec 2020 (S) | Dec 2021 (S) | Dec 2022 (S) | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21 | 24 | 22 | 29 | 21 | 27 | 19 | 18 | 17 | 24 | 42 |
| Inventory Days | 179 | 173 | 169 | 151 | 154 | 127 | 107 | 110 | 125 | 254 | 186 |
| Days Payable | 122 | 81 | 79 | 119 | 110 | 100 | 93 | 105 | 109 | 112 | 151 |
| Cash Conversion Cycle | 78 | 115 | 112 | 61 | 65 | 54 | 33 | 22 | 33 | 167 | 77 |
| Working Capital Days | 26 | 9 | 79 | 17 | 18 | 35 | -8 | -20 | -19 | 35 | 20 |
| ROCE % | 22% | 26% | 27% | 26% | 29% | 28% | 32% | 35% | 41% | 49% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Employees count |
|
||||||||||
| Number of Countries Exported To count |
|||||||||||
| Production Volume at Manufacturing Sites (Total Galenic Units) billion units |
|||||||||||
| Number of Distributors count |
|||||||||||
| Lantus Market Share in Basal Insulin Segment % |
|||||||||||
| Manufacturing Cost per Unit at Goa Site USD per unit |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Update On Show Cause Notice Received From GST Authorities Dated 25Th September 2026
- Bengaluru GST show cause notice dropped; Sanofi India pays Rs.17,680 tax and interest on 16 November 2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Communication Of Tax Deduction At Source On Interim Dividend For The Financial Year 2026
- Sanofi India declared Rs 75 interim dividend for FY2026; record date 5 November 2026.
-
Announcement under Regulation 30 (LODR)-Dividend Updates
- Sanofi India reported Q3 FY2026 results and declared ₹75 interim dividend; record date is 5 November 2026.
- Record Date For Interim Dividend For The Financial Year 2026
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2013
from nse
-
Annual Report 2012
from bse
Concalls
-
Aug 2026Transcript PPT REC
-
Mar 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript
-
Feb 2024Transcript
-
Nov 2023Transcript
-
Nov 2023Transcript
-
May 2023Transcript
-
May 2023Transcript
-
Feb 2023Transcript
-
Feb 2023Transcript
-
Mar 2021PPT
Parent Company:[1]
Sanofi Global and its 100% subsidiary - Hoechst GmbH, are the shareholders of Sanofi India and together hold 60.40%. Company's follows parent company's financial year hence, Financial year is same as Calender Year.